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Abstract
Subretinal injection of sodium hyaluronate is a widely accepted method of inducing retinal detachment (RD)
1-15. However, the height and duration
of RD or the occurrence of subretinal hemorrhage can affect photoreceptor cell death in the detached retina
16-21. Hence, it is advantageous to
create reproducible RDs without subretinal hemorrhage for evaluating photoreceptor cell death. We modified a previously reported method to
create bullous and persistent RDs in a reproducible location with rare occurrence of subretinal hemorrhage. The critical step of this modified
method is the creation of a self-sealing scleral incision, which can prevent leakage of sodium hyaluronate after injection into the subretinal space.
To make the self-sealing scleral incision, a scleral tunnel is created, followed by scleral penetration into the choroid with a 30 G needle. Although
choroidal hemorrhage may occur during this step, astriction with a surgical spear reduces the rate of choroidal hemorrhage. This method
allows a more reproducible and reliable model of photoreceptor death in diseases that involve RD such as rhegmatogenous RD, retinopathy of
prematurity, diabetic retinopathy, central serous chorioretinopathy, and age-related macular degeneration (AMD).
Video Link
The video component of this article can be found at http://www.jove.com/video/50660/
Introduction
Photoreceptor cell death and subsequent visual decline occurs when the photoreceptors are separated from the underlying retinal pigment
epithelium. Physical separation of photoreceptors is seen in various retinal disorders, including age-related macular degeneration (AMD), central
serous chorioretinopathy, diabetic retinopathy, and retinopathy of prematurity, as well as rhegmatogenous (i.e. caused by a break in the retina)
retinal detachment (RD). Subretinal injection of sodium hyaluronate is a widely accepted model to create an RD that leads to photoreceptor cell
death, providing insight into the pathophysiology of photoreceptor degeneration
1-15.
Photoreceptor degeneration induced by subretinal sodium hyaluronate injection, first introduced in 2001
7, has the advantage of a reasonable
time course (days to weeks). However, it can have significant variability of photoreceptor cell loss from animal to animal due to two major factors
that affect photoreceptor cell death after RD: 1) height and duration of the RD, and 2) the occurrence of subretinal hemorrhage. There is a steep
technical learning curve to the method that contributes to both factors. Photoreceptor cell degeneration increases with the height of the RD, as
the distance between the retinal pigment epithelial (RPE) layer and photoreceptors increases
16-17. Consistent with these reports, our previous
experiments showed more photoreceptor death in bullous RDs than shallow RDs. It has also been reported that subretinal hemorrhage is toxic
for photoreceptor cells and affects photoreceptor cell death
18-21. Likewise, we have observed more photoreceptor death in RDs with subretinal
hemorrhage than RDs without subretinal hemorrhage. Hence, techniques to minimize variability have to focus on achieving consistent heights of
RD while avoiding subretinal hemorrhage.
Our modified method of inducing RD can make reproducible bullous and persistent RD at the same position of the eye with rare occurrence of
subretinal hemorrhage. We performed surgery using a temporal approach because it is easier to achieve a wider operative field compared with
other sites. After the conjunctival incision, a self-sealing scleral incision is made using a 30 G needle. A scleral tunnel is created, followed by
scleral penetration into the choroid. If choroidal bleeding occurs in this step, the hemorrhage will exit the eye through the scleral wound, and
the bleeding can be stopped by astriction with a surgical spear. An anterior chamber puncture is then performed from the cornea to reduce
intraocular pressure. This is an important step because subretinal injection alone will lead to increased intraocular pressure with resultant retinal
artery occlusion and ischemia of the inner retina. A 33 G needle connected to a Hamilton 10 μl syringe is then inserted into the subretinal space,
and 3.5 μl sodium hyaluronate is gently injected to detach the neurosensory retina from the underlying RPE. In contrast to other methods of
inducing RD that are performed under fundus observation, this technique is performed under direct observation. Since the scleral wound is
self-sealing, sodium hyaluronate will not leak out after injection. Finally, glue is put on the scleral wound, and the conjunctiva is reattached to
its original position. These lasts steps also reduce the risk of sodium hyaluronate leakage. The injection of 3.5 μl sodium hyaluronate creates
reproducible RDs (50% of the retina) in the eyes of 8-week-old mice. Creating the self-sealing wound is the most important step in our modifiedJournal of Visualized Experiments www.jove.com
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procedure because it prevents the injected sodium hyaluronate from leaking out of the eye, thus allowing reproducible bullous and persistent
RDs.
Protocol
All experiments on animals were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research, and the guidelines and regulations set forth by the Massachusetts Eye and Ear Infirmary Animal
Care Committee.
1. Pretreatment
1. Anesthetize an 8-week-old mouse with an intraperitoneal injection of a mixture of 60 mg/kg ketamine and 6 mg/kg xylazine.
2. Cut the whiskers. This is done because they interfere with visualization and instrument placement.
3. Dilate the pupil with 5% phenylephrine and 0.5% tropicamide.
4. Cut the cilia. This is also done because they interfere with visualization and instrument placement.
5. Apply topical anesthesia (0.5% proparacaine hydrochloride ophthalmic solution).
2. Surgery Under the Microscope
1. Set the mouse in a lateral position with the nose toward the surgeon. A toe pinch is performed to confirm surgical anesthesia, and sterile
gloves are donned prior to starting surgery.
2. Incise the temporal conjunctiva at the posterior limbus and separate the conjunctiva from the sclera. Avoid penetrating the sclera. After this
step, grasp the conjunctiva at the limbus with forceps to control the eye.
3. Make a self-sealing scleral incision using the tip of a 30 G needle with the bevel pointed up. Make a scleral tunnel through the sclera and
penetrate the sclera into the choroid (Figure 1). Avoid penetrating the retina. If choroidal bleeding occurs and comes out through the scleral
wound, perform an astriction with a surgical spear until the bleeding stops. This scleral wound will be self-sealed with intraocular pressure.
4. Puncture the cornea with a 30 G needle to reduce intraocular pressure. Use the needle parallel to the iris to avoid injuring the iris and lens
during entry into the anterior chamber. The intraocular pressure will cause the wound to self-seal.
5. Insert a 33 G needle connected to a Hamilton 10 μl syringe into the subretinal space with the bevel pointed down (towards the inner eye), and
inject 3.5 μl sodium hyaluronate gently to detach the neurosensory retina from the underlying RPE. Avoid penetrating the retina with the 33
G needle because sodium hyaluronate will go into the vitreous space but not the subretinal space if the retina is penetrated. Also, avoid rapid
injection because it will create an oral tear, and sodium hyaluronate will leak into the anterior chamber.
6. Let the aqueous humor ﬂow out from the corneal puncture by pushing the cornea around the corneal puncture with forceps to adjust the
intraocular pressure.
7. Confirm absence of leakage from the scleral wound using a surgical spear.
8. To reduce the risk of sodium hyaluronate leakage, place cyanoacrylate surgical glue on the scleral wound.
9. Reattach the conjunctiva to its original position using cyanoacrylate surgical glue. This will further reduce the risk of sodium hyaluronate
leakage.
10. Check the fundus using a cover glass and confirm the creation of a bullous RD without subretinal hemorrhage.
3. After Treatment
1. Apply bacitracin antibiotic ointment to the eye to reduce the risk of infection.
2. Keep the mice on a heating pad to prevent the anesthesia (mixture of ketamine and xylazine) from causing low body temperature subsequent
to low blood pressure.
3. Put the mice back to the animal cage after they awaken from anesthesia. Monitor the mice daily for complications. If any complications arise,
euthanize the mice as described below.
4. Sacrifice
1. Euthanize the mice by cervical dislocation after intraperitoneal injection of 100 mg/kg sodium pentobarbital, and enucleate the eyes at
appropriate time points for each experiment (not shown). Avoid applying pressure on the eye during enucleation because sodium hyaluronate
may leak out. Bullous RDs should be persistent for at least 14 days.
Representative Results
To assess the persistence of the RD made by this protocol, cryosections were made on days 3, 7, and 14 after induction of RD. Six eyes were
used for each time point. Hematoxylin and eosin (HE) staining was used to visualize the sections. All sections showed a bullous RD approaching
the lens (Figure 2). One eye showed subretinal hemorrhage on day 7. No eyes showed any signs of infection or lens injury.Journal of Visualized Experiments www.jove.com
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Figure 1. Creating a self-sealing scleral incision. This schematic shows a cross-sectional image of a normal mouse eye. Red line indicates
the self-sealing scleral incision. A scleral tunnel followed by scleral penetration into the choroid with a 30 G needle creates a self-sealing scleral
incision. This scleral wound will be self-sealed with intraocular pressure, which can prevent leakage of sodium hyaluronate after injection into the
subretinal space and achieve persistent bullous retinal detachments.
 
Figure 2. Time course of retinal detachment.  This fundus photo shows a bullous retinal detachment without subretinal hemorrhage
immediately after surgery. Cryosections with hematoxylin and eosin (HE) staining show persistent bullous retinal detachment without subretinal
hemorrhage through at least day 14.
Discussion
Several methods for establishing an RD model in rodent eyes have been reported
3-15, 22. Most of them utilize subretinal injection of sodium
hyaluronate because it is a viscous material commonly used during intraocular surgery in humans, and it is not associated with any known ocular
toxicity
1-15. Sodium hyaluronate, rather than normal saline or phosphate-buffered saline (PBS), increases the duration of the RD.
The methods for subretinal injection of sodium hyaluronate use one of two approaches: a transvitreal approach
3-6 or a transscleral approach
7-15.
Both methods are performed with observation of the fundus. In the transvitreal approach, a subretinal injector is introduced into the vitreous
cavity, a retinotomy is created in the peripheral retina, and the sodium hyaluronate is injected into the subretinal space. In this method, two retinal
tears are made, which increases the risk of retinal hemorrhage that might go into the subretinal space. In addition, there is a risk of lens injury
when the retinotomy is created. There are several modified methods for the transscleral approach. In most of these methods
7-12, after reducing
intraocular pressure with an anterior chamber puncture, a 30 G needle connected to a syringe filled with sodium hyaluronate is directly insertedJournal of Visualized Experiments www.jove.com
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into the subretinal space through the conjunctiva, sclera, choroid, and RPE. The sodium hyaluronate is then injected into the subretinal space.
The risk of retinal tear and lens injury using this transscleral method is less than that using the transvitreal approach. However, the hole made in
the sclera by a 30 G needle is large, especially for mouse eyes, and the sodium hyaluronate injected into the subretinal space easily leaks out of
the eye through the scleral wound. This leads to a lower, less persistent RD and more variable photoreceptor cell death. Moreover, if choroidal
bleeding occurs in the scleral perforation step, the hemorrhage will spread into the subretinal space because the intraocular pressure has been
reduced prior to the subretinal hyaluronate injection.
Several factors can influence the effect of RD on the detached retina, including both subretinal hemorrhage and the height and persistence of
RD
16-21. Photoreceptor cell death increases with increasing height of RD
16, 17, and photoreceptor cell damage may be more extensive because
of reduced diffusion of oxygen and essential nutrients from the choriocapillaris with higher RD compared to shallow RD. Subretinal hemorrhage
is also toxic for photoreceptor cells
18-21; possible mechanisms of this toxicity in the detached retina include hypoxia and metabolic disruption
by subretinal hemorrhage as a diffusion barrier, and direct neurotoxicity induced by blood components (such as iron). Lens injury, which has
been reported to have a protective effect on retinal ganglion cells
23, may also affect photoreceptor cell death after induction of RD. In addition,
if the entry wound site is not sealed, sodium hyaluronate may leak out with eye manipulation during enucleation. This may lead to erroneous
classification of an RD as shallow, which may in turn affect the interpretation of the results.
We modified the transscleral method for subretinal injection of sodium hyaluronate to increase the reproducibility of RDs and reduce the rate of
subretinal hemorrhage. The critical step of this protocol is creating a self-sealing scleral incision using a 30 G needle, which prevents leakage
of sodium hyaluronate after injection. Unlike previous methods, this protocol is performed without observation of the fundus so greater attention
is paid to the scleral wound. Application of glue also prevents the sodium hyaluronate from leaking out of the eye. In our experience, the rate
of subretinal hemorrhage with this protocol was significantly less than that with other protocols. If choroidal bleeding occurs during the scleral
incision step, it will exit the eye through the scleral wound because this step is performed before reducing intraocular pressure. If choroidal
bleeding does occur after reduction of the intraocular pressure and detachment of the neurosensory retina, blood will dissect into the subretinal
space. We found this to happen in about 5% of the cases in contrast to about 10-20% with the other techniques. These animals should be
excluded from analysis.
This technique can also be used for subretinal injection of vector-mediated gene transfer to target photoreceptor or RPE cells
24, 25. Because the
typical vehicle (PBS, saline) for these injections is significantly less viscous than sodium hyaluronate, standard techniques are plagued by more
leaks. The technique described herein, by reducing this risk, makes vector transfer experiments more reproducible and reliable.
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